There are multiple approaches to gaining a foothold within the bioprocessing industry, but small firms sometimes overlook how capturing the attention of a large firm early in their product development process may pay off in the future.
Firms entering the bioprocessing market should understand their customers' purchasing criteria, which largely stems from regulatory demands.
The FDA defined the process analytical technologies (“PAT”) framework to optimize the control and monitoring of bioprocessing.
In recent years, the focus on polymers in single-use films within the biologics industry has moved from niche detail to critical importance.
Biopharma customers have strict sourcing criteria. Understanding biopharma constraints is crucial for firms looking to enter the industry.